David Ricks, Chair and C.E.O. of Eli Lilly and Company, speaks during the New York Times annual DealBook summit at Jazz at ...

In early 2018, Dave Ricks, the chief executive of the pharmaceutical giant Eli Lilly LLY-0.30%decrease; red down pointing triangle, was on a West Coast college tour with his daughter when his ...

Presiding over the upward trajectory of Eli Lilly over the last eight years has been paying off nicely for CEO David Ricks. In 2024, his compensation package grew to $29.2 million, according to ...

However, some major executives in the sector are not optimistic, including Eli Lilly's (NYSE: LLY) CEO, David Ricks. Let's see what he had to say about the potential impact of tariffs, and what ...

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type 2 diabetes. Previous versions were administered via injection.

When David Ricks became CEO of Eli Lilly, he faced the usual pressures of making the right, albeit risky, bets on the next big pharmaceutical breakthrough. But he also faced a unique challenge—t ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly is getting closer to bringing a weight loss pill to market, but CEO David Ricks notes certain factors need to be considered to prevent prices from ballooning. The Trump administration ...

However, some major executives in the sector are not optimistic, including Eli Lilly's (NYSE: LLY) CEO, David Ricks. Start Your Mornings Smarter! Wake up with Breakfast news in your inbox every ...

Eli Lilly (LLY) CEO David Ricks got a 10% raise in 2024, as a surge in demand for weigh-loss drugs has propelled the pharma giant into the most valuable pharmaceutical company in the world.

David Ricks thinks Trump's tariffs will eventually target drugmakers. The results could be harmful to them in more ways than one. Despite this issue, Eli Lilly remains a top stock to buy.